Scientists
A new report from researchers in Edgbaston, the United Kingdom, has shed light on the role of tetraspanin CD151 in regulating the glycosylation of (alpha)3(beta)1 integrin. The study found that down-regulation of CD151 in epithelial cell lines altered the glycosylation of alpha3beta1, with a significant reduction in
Universities and colleges
Scribble (Scrib) is a crucial protein in establishing epithelial polarity, and recent research has shed light on its interactions with other proteins. According to a study published in the Journal of Cellular Biochemistry, Scrib's Leucine-rich-repeat (LRR) and PDS-95/Discs Large/ZO-1 (PDZ) domains independently associate with the plasma
Universities and colleges
Scientists at Pennsylvania State University have made significant discoveries in the field of medical research, shedding light on new avenues for combating cancer and understanding cellular processes. The studies highlight the potential for innovative treatments and diagnostic tools, paving the way for future advances in healthcare. Key Takeaways: * Study 1:
Universities and colleges
Investigations into the molecular mechanisms underlying glucose metabolism in the liver have led to the discovery of ChREBP*Mlx as the primary transcription factor regulating glucose-induced gene expression. Scientists at the University of Minnesota Department of Biochemistry have identified a modified ChoRE consensus sequence, CAYGNGN(5)CNCRTG, which is crucial
Universities and colleges
Scientists in the United States have identified a significant exception to the conventional understanding of glucose effects on cellular functions. The study, led by A.H. Minn and colleagues at the University of Wisconsin, reveals that a non-metabolizable sugar called 3-O-methylglucose (3-MG) can stimulate the expression of thioredoxin-interacting protein (TXNIP)
Pharmaceutical industry
Anergen, Inc. has announced a significant partnership with Sunol Molecular Corp. to develop a treatment for multiple sclerosis. The collaboration has led to the creation of a novel, recombinant form of a major histocompatibility complex class II (MHC-II) molecule, which is a crucial component of Anergen's proprietary platform
Pharmaceutical industry
Tularik Inc., a biotechnology company focused on the discovery and development of therapeutic agents, and Japan Tobacco Inc. (JT), a diversified company with a significant presence in the pharmaceutical industry, announced a three-year collaborative agreement to develop agonists and antagonists of orphan nuclear receptors. This agreement marks the second collaboration
Pharmaceutical industry
Cognetix, Inc. has raised $6 million in venture financing to advance its programs to discover and develop novel therapeutics based on highly specific bioactive compounds from marine organisms. The funding enables the company to advance its lead product development programs and expand its proprietary library of over 130 fully characterized,
Pharmaceutical industry
Cerep SA, a French drug discovery company, has signed an agreement with Xenometrix Inc., a US biotechnology company, granting Cerep access to Xenometrix's technology for gene expression profiling. This partnership will enable Cerep to investigate gene response profiles of compounds, increasing efficiency and lowering costs in drug lead
Pharmaceutical industry
British Biotech and Glaxo Wellcome have announced a significant agreement for the development of BB-2983, a novel oral treatment for arthritis. The deal marks a crucial step forward in bringing a potentially groundbreaking therapy to market. Under the agreement, Glaxo Wellcome will take over the development and marketing of BB-2983,
Pharmaceutical industry
As the 1996 new year approaches, Allergan Inc. is poised to maintain its momentum with a seasoned management team. Following Gavin Herbert's retirement as an executive officer and employee in March 1994, the board of directors has now decided to transition the chairman role to William C. Shepherd,
Medical equipment industry
ID Biomedical Corporation has announced the appointment of Dr. Robert N. Bryan as Vice President, Development, a move that is expected to bring significant expertise in DNA-based testing to the company. Dr. Bryan has a proven track record of developing and introducing FDA-approved DNA-based tests, and his experience will be
